CA1040533A - Controlled gastric residence medicament formulation - Google Patents

Controlled gastric residence medicament formulation

Info

Publication number
CA1040533A
CA1040533A CA173,291A CA173291A CA1040533A CA 1040533 A CA1040533 A CA 1040533A CA 173291 A CA173291 A CA 173291A CA 1040533 A CA1040533 A CA 1040533A
Authority
CA
Canada
Prior art keywords
cross
parts
weight
formulation according
prepolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA173,291A
Other languages
English (en)
French (fr)
Inventor
Gilbert S. Banker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Application granted granted Critical
Publication of CA1040533A publication Critical patent/CA1040533A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA173,291A 1972-06-09 1973-06-06 Controlled gastric residence medicament formulation Expired CA1040533A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26124272A 1972-06-09 1972-06-09

Publications (1)

Publication Number Publication Date
CA1040533A true CA1040533A (en) 1978-10-17

Family

ID=22992462

Family Applications (1)

Application Number Title Priority Date Filing Date
CA173,291A Expired CA1040533A (en) 1972-06-09 1973-06-06 Controlled gastric residence medicament formulation

Country Status (19)

Country Link
JP (1) JPS4961323A (pl)
AU (2) AU5682673A (pl)
BE (1) BE800637A (pl)
CA (1) CA1040533A (pl)
CH (1) CH582002A5 (pl)
DD (2) DD109309A5 (pl)
DE (1) DE2328580A1 (pl)
ES (1) ES415624A3 (pl)
FR (1) FR2187290B1 (pl)
GB (1) GB1428426A (pl)
HU (1) HU167947B (pl)
IE (1) IE38151B1 (pl)
IL (1) IL42459A (pl)
NL (1) NL7307737A (pl)
OA (1) OA04931A (pl)
PL (1) PL90109B1 (pl)
RO (1) RO64146A (pl)
SE (1) SE395609B (pl)
ZA (1) ZA733897B (pl)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421178B2 (en) 2011-12-02 2016-08-23 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US10166207B2 (en) 2013-06-05 2019-01-01 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207890A (en) 1977-01-04 1980-06-17 Mcneilab, Inc. Drug-dispensing device and method
JPS5911563B2 (ja) * 1980-02-27 1984-03-16 日本原子力研究所 多層構造の徐放性複合体を製造する方法
US4518433A (en) * 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
DE3314003A1 (de) * 1983-04-18 1984-10-18 Boehringer Ingelheim KG, 6507 Ingelheim Teilbare tablette mit verzoegerter wirkstofffreigabe und verfahren zu deren herstellung
US4657784A (en) * 1986-03-10 1987-04-14 Ecolab Inc. Process for encapsulating particles with at least two coating layers having different melting points
ATE71293T1 (de) * 1986-09-18 1992-01-15 London Pharmacy Innovation Arzneiformulierung.
US4837030A (en) * 1987-10-06 1989-06-06 American Cyanamid Company Novel controlled release formulations of tetracycline compounds
AU614328B2 (en) * 1988-02-01 1991-08-29 Mayne Pharma International Pty Ltd Tetracycline dosage form
EP0327295A3 (en) * 1988-02-01 1989-09-06 F.H. FAULDING & CO. LTD. Tetracycline dosage form
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
AU767812B2 (en) 2000-02-04 2003-11-27 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1050353B (it) * 1966-01-06 1981-03-10 Ceskoslovenska Akademie Ved Supporti per sostanze biologigamente attive
AU454482B2 (en) * 1970-11-05 1974-10-15 Alza Corporation Drug-delivery system

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421178B2 (en) 2011-12-02 2016-08-23 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9421179B2 (en) 2011-12-02 2016-08-23 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9427420B2 (en) 2011-12-02 2016-08-30 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US10512621B2 (en) 2011-12-02 2019-12-24 Synchroneuron, Inc. Methods of treating posttraumatic stress disorder with acamprosate salts
US10166207B2 (en) 2013-06-05 2019-01-01 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same

Also Published As

Publication number Publication date
ZA733897B (en) 1975-01-29
HU167947B (pl) 1976-01-28
IE38151B1 (en) 1978-01-04
JPS4961323A (pl) 1974-06-14
IE38151L (en) 1973-12-09
ES415624A3 (es) 1976-10-16
IL42459A0 (en) 1973-08-29
DD112354A5 (pl) 1975-04-12
RO64146A (fr) 1978-11-15
IL42459A (en) 1976-12-31
AU5682673A (en) 1974-12-12
DD109309A5 (pl) 1974-11-05
BE800637A (fr) 1973-12-07
FR2187290A1 (pl) 1974-01-18
OA04931A (fr) 1980-10-31
AU5935773A (en) 1975-02-20
CH582002A5 (pl) 1976-11-30
SE395609B (sv) 1977-08-22
PL90109B1 (pl) 1977-01-31
FR2187290B1 (pl) 1977-04-15
NL7307737A (pl) 1973-12-11
DE2328580A1 (de) 1974-01-10
GB1428426A (en) 1976-03-17

Similar Documents

Publication Publication Date Title
CA1040533A (en) Controlled gastric residence medicament formulation
Saffran et al. A new approach to the oral administration of insulin and other peptide drugs
EP0235718B1 (en) Granule remaining in stomach
US5068110A (en) Stabilization of enteric coated dosage form
JP4963767B2 (ja) 制御放出性製剤の製法
EP0662321B1 (en) Method for producing osmosis-controlled tablets avoiding the use of chlorinated hydrocarbons
US5183829A (en) Oral liquid compositions of non-steroidal anti-inflammatory drugs
JP5425058B2 (ja) アルギン酸塩体を含む胃内滞留型システム
Chitnis et al. Bioadhesive polymers-synthesis, evaluation and application in controlled release tablets
HRP980379A2 (en) Sertraline salts and sustained-release dosage forms of sertraline
US4088798A (en) Methods for the preparation of controlled gastric residence time medicament formulations
JP2002522473A (ja) 経口投与の固形投与形態物としてのマイクロエマルション
EA011373B1 (ru) Модифицированное высвобождение фармацевтической композиции
Kono et al. pH-responsive permeability of poly (acrylic acid)—poly (ethylenimine) complex capsule membrane
EP0313845A1 (en) Stabilization of enteric coated dosage form
Ogata et al. Development and evaluation of a new peroral test agent GA-test for assessment of gastric acidity
Kashid et al. Studies on rebamipide loaded gastroretentive alginate based mucoadhesive beads: Formulation & in-vitro, in-vivo evaluation
Li et al. Water based silicone elastomer controlled release tablet film coating III-Drug Release Mechanisms
Murthy et al. In vitro release characteristics of hard shell capsule products coated with aqueous-and organic-based enteric polymers
Gadad et al. Sodium alginate polymeric floating beads for the delivery of cefpodoxime proxetil
WO1997034580A1 (en) Suppository composition of the drug which has gastro-intestinal disturbances or undergoes the decomposition by gastric acid
Shieh et al. 5-Aminosalicyclic acid permeability enhancement by a pH-sensitive EVAL membrane
Jain et al. Controlled release calcium silicate based floating granular delivery system of ranitidine hydrochloride
Jalil et al. Effect of viscosity increasing agent and electrolyte concentration on the release rate of theophylline from a HPMC based sustained release capsules
WO1992007553A1 (en) Coating or matrix material for medicaments